Contract research organisation (CRO) Quintiles Transnational has boosted its UK marketing teams through a deal with Nycomed but is planning cutbacks at US operations in RTP.

In a deal announced late last week, a UK based health solutions teams run by Nycomed will transfer to Quintiles while continuing to work with the Swiss drugmaker on a contractual basis.

Nycomed said that the deal, which follows the formations of its UK focused co-marketing agreement with US drugmaker Merck & Co for the chronic obstructive pulmonary disease (COPD) drug Daxas, is a “win-win” situation.

Melissa Thomas, Nycomed’s UK MD, said: “The team has continued employment in an exciting new healthcare model and will be exposed to new opportunities through global industry leader Quintiles; whereas Nycomed continues to have access to their expertise.”

Read More....